(MedPage Today) — Thirty warning letters were issued to telehealth companies for false and misleading claims about compounded GLP-1 receptor agonist products, the FDA announced on Tuesday.
The letters primarily targeted claims implying “sameness…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
